$GEHC

Jeannette Bankes will step down as President and CEO of GE HealthCare's Patient Care Solutions business on November 15, 2026. The company has not disclosed a reason for her departure or a replacement. This news was reported in an SEC filing by GE HealthCare Technologies Inc. (GEHC).

GE HealthCare Technologies Inc. (GEHC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99 GE HealthCare reports third quarter 2026 financial results • Delivers top- and bottom-line growth ahead of Company expectations and raises full-year 2026 guidance • Revenue growth of 7.2%, and Organic revenue growth* of 6.2% • Organic orders growth of 4.0% , book-to-bi

GE HealthCare Technologies reported Q3 Non-GAAP EPS of $1.34, exceeding estimates by $0.14, with revenue of $5.51B, up 7.2% Y/Y and beating by $160M. The company also raised its FY guidance. According to GEHC, organic orders grew 4.0%, with a book-to-bill ratio of 1.03 and a backlog of $23.7B.

GE HealthCare acquired SOFIE Biosciences, a US contract manufacturer of F-18 tracers, to secure supply capacity and support its $500M revenue target for Flyrcado by 2028. The deal mirrors Siemens Healthineers' model and addresses GE's reliance on external manufacturers. SOFIE also produces tracers for Lantheus, a competitor soon to be acquired by Curium. Analyst Ashley Clarke notes the move reduces risk but may not significantly increase market share.

AstraZeneca (AZN) received FDA approval for Ultomiris in IgA nephropathy, with a 43.4% reduction in proteinuria. Merck (MRK) got EU approval for KEYTRUDA plus Padcev in bladder cancer, showing a 35% reduction in death risk. Alvotech (ALVO) approved a new manufacturing process for SIMLANDI. Cytokinetics (CYTK) won Health Canada approval for MYQORZO in obstructive HCM. Viatris (VTRS) approved RYZUMVI for presbyopia. Enlivex (ENLV) and EyePoint (EYPT) announced significant workforce reductions.

GE HealthCare (GEHC) announced a global clinical evaluation program for its StarGuide GX, a next-generation digital 4D SPECT/CT system, involving five institutions across three continents. The program aims to assess image quality, quantitative performance, and workflow, with insights guiding future platform evolution. StarGuide GX uses advanced detector technology and is designed for high-sensitivity, high-resolution imaging.

GE HealthCare launched the LOGIQ Focus ultrasound system, featuring AI automation and advanced imaging. A study showed 90% rated image quality as excellent, and it demonstrated 26% faster performance. The system includes productivity tools and cybersecurity features. GE HealthCare expects it to contribute 1% to 2% of revenue growth. The product has received regulatory approvals and is available in approved markets.

GE HealthCare (GEHC) announced a study showing its End-tidal Control software reduced anesthetic gas usage by 62.3% and sevoflurane consumption by 39.3%. The company is deemed modestly undervalued with a GF Value of $84.94 vs. current price $70.35, and a GF Score of 73/100. Insiders have bought $6.3M in shares over 12 months.

GE HealthCare announced its PETtrace Solid Target Platform will now support Copper-64 production, expanding beyond Gallium-68 and Zirconium-89. This addition allows for a broader range of isotopes, potentially benefiting research in theranostics and cancer treatments like prostate and breast cancer. The company's full capabilities aim to support institutions in establishing radiopharmacy workflows.

GE HealthCare (GEHC) received CE Mark approval for its compact cyclotron, MINItrace Magni, for local production of PET imaging isotopes. The device supports fluorine-18 and other isotopes, enabling in-house supply of agents like Flyrcado. GEHC also expanded its PETtrace cyclotron's capabilities to include copper-64 for research, potentially aiding prostate and breast cancer diagnostics.